ERBB2 is altered in 8.97% of extrahepatic cholangiocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for extrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and extrahepatic cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FGF19 is altered in 4.51% of extrahepatic cholangiocarcinoma patients [2].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 1.32% of extrahepatic cholangiocarcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is altered in 1.31% of extrahepatic cholangiocarcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 is altered in 3.27% of extrahepatic cholangiocarcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR4 is altered in 0.66% of extrahepatic cholangiocarcinoma patients [2].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].